Appropriate levels of cytotoxicity for genotoxicity tests using mammalian cells in vitro
Post on 06-Jun-2016
Embed Size (px)
Appropriate Levels of Cytotoxicity for Genotoxicity TestsUsing Mammalian Cells In Vitro
Lutz Muller1* and Toshio Sofuni21Federal Institute for Drugs and Medical Devices, Berlin, Germany
2National Institute of Health Sciences, Tokyo, Japan
Among standard battery genotoxicity assays, thein vitro chromosome aberration test and the mouselymphoma tk assay (MLA) yield about fourfoldhigher incidences of positive test results than thebacterial reverse mutation test or in vivo bone mar-row tests. This is a result of experience with sub-missions of 335 new pharmaceuticals to the Ger-man Federal Institute for Drugs and MedicalDevices. While all of the standard systems havetheir value in detecting relevant genotoxins, thereis no supportive evidence for DNA reactivity for aconsiderable number of in vitro clastogens andMLA positives. In particular the clastogenic re-sponse of such compounds is often associated withhigh cytotoxicity. This may invoke the need to
change the approach to test for clastogenicity invitro. A combination of measures such as (1) achange in the upper limits of cytotoxicity that arecurrently given in International Conference on Har-monisation (ICH) and Organization for EconomicCo-Operation & Economic Development (OECD)guidelines, (2) the creation of a common ground ofunderstanding for interpretation of in vitro (posi-tive) test results, and (3) lowering the upper limits oftest compound concentration irrespective of cyto-toxicity may prove useful to ensure a sufficientreliability of genotoxicity testing with mammaliancells in vitro. Environ. Mol. Mutagen. 35:202205,2000. 2000 Wiley-Liss, Inc.
Key words: cytotoxicity in vitro; mammalian cells; threshold; chromosome aberrations
The analysis of standard genotoxicity test data that havebeen conducted for safety evaluation of chemical com-pounds usually reveals a fairly high percentage of positiveresults, in particular in the in vitro chromosome aberrationtest and in the mouse lymphoma tk assay (MLA). Table Iillustrates this on the basis of experience with submissionsfor registration of 335 new pharmaceutical entities to theGerman Federal Institute for Drugs and Medical Devices.Both the in vitro chromosome aberration test and the MLAyielded positive results for more than 25% of the pharma-ceuticals tested. The percentage of positives in this databaseis somewhat higher than the 18% positives/equivocals re-ported for the aberration test by Galloway (2000) for a totalof 1,420 compounds tested. One reason may be differentcriteria for a positive call.
The positive results in mammalian cells in vitro forpharmaceutical compounds are reflecting a variety of com-pound groups with different mechanisms of action. Tradi-tional alkylating agents or other compounds with knowngenotoxic potential, such as nucleoside analogues or gyraseinhibitors are only a fraction (approximately 25%) of thosethat yielded positive test results, in particular in mammaliancells in vitro. For quite a substantial percentage of com-pounds, there was no immediate obvious and convincingrationale that would have helped to reason for the positivetest results. Yet, distinct cytotoxicity was frequently noted
at concentrations that showed an increased incidence ofchromosome aberrations or an increase in mutation fre-quency for the MLA. The overwhelming majority of thesecompounds yielded negative results in the in vivo part of thegenotoxicity battery and was negative regarding genotoxi-city related tumor findings in rodent 2-year bioassays. Afull review of the data is provided in Muller and Kasper.
Although genotoxicity is usually associated with cytotox-icity, most known genotoxic carcinogens will yield positiveeffects in the in vitro assays already at low levels of cyto-toxicity but proceeding well into the cytotoxic range [Gal-loway et al., 1998; Galloway, 2000]. On the other hand, aclose association of genotoxicity, in particular chromosomedamage, with high toxicity has in some cases been evaluatedas nonrelevant or thresholded genotoxicity, although theexact mechanisms of action have not been found in mostcases [Muller et al., 1991; Armstrong et al., 1992; Kirkland,1992; Galloway et al., 1998; Hilliard et al., 1998; Kirklandand Muller, 2000; Muller and Kasper, 2000].
Among the various groups of new pharmaceutical com-pounds with structural and/or pharmacological similaritiesthat clearly display positive effects in the in vitro chromo-
T. Sofuni is currently at Olympus Optical Co. Ltd., Tokyo, Japan.
*Correspondence to: Lutz Muller, Federal Institute for Drugs and MedicalDevices, Seestr. 10, 13353 Berlin, Germany. E-mail: L.email@example.com
Environmental and Molecular Mutagenesis 35:202205 (2000)
2000 Wiley-Liss, Inc.
some aberration test, two may be of particular interestbecause of their widespread medical use in recent years: (1)angiotensin-converting enzyme (ACE) inhibitors and (2)angiotensin II receptor (AIIR) antagonists. In Germany,there are nine ACE inhibitors and seven AIIR antagonistsmarketed. Among them, five ACE inhibitors and five AIIRantagonists induced chromosome aberrations in vitro inhuman lymphocytes or established cell lines with differentlevels of potency; one ACE inhibitor yielded up to 91%aberrant metaphases. All compounds showed marked reduc-tion in cell count, mitotic index, culture confluency, or BrdUuptake at concentrations yielding chromosome damage.There was no evidence for genotoxicity in bacteria or invivo. Furthermore, rodent carcinogenicity studies did notyield tumors that might be genotoxicity related. DNA syn-thesis inhibition has been suggested as one possible mech-anism supporting an indirect mechanism of aberration in-duction for AIIR antagonists [Galloway et al., 1998]. Inaddition to these examples, an extensive review of geno-toxicity data of paracetamol (synonymous to acetamino-phen) provides evidence that widely used compounds canbe convincingly genotoxic, i.e., inducers of chromosomedamage in vitro and in vivo, yet with convincing data for athreshold-related mechanism, their safe use can be advo-cated [Bergman et al., 1996].
Experience with regulation of such cases as describedabove shows that there appears to be not enough commonunderstanding on how to evaluate the relevance of each case[Kirkland and Muller, 2000; Muller and Kasper, 2000]. Thishas been a cause for concern for some time, and problemsof nonrelevant genotoxicity in vitro have been discussed byan ICPEMC group [Scott et al., 1991] and has been a topicat a Japanese Environmental Mutagen Society (JEMS)meeting as early as in 1984 [Tazima et al., 1984]. Inprinciple, guidelines such as those given by OECD or ICH52A or 52B offer the possibility to describe and refineprotocols that avoid an excess number of nonrelevant pos-itives and allow for the inclusion of appropriate criteria forjudgement. Table II provides criteria mentioned in the ICH
S2A guidance regarding interpretation of test results andmakes clear that in the pharmaceutical area there is regula-tory acceptance of conditions that may account for nonrel-evant genotoxicity.
The definition of upper limits for cytotoxicity has been animportant issue in the update of the relevant OECD guide-lines and in the creation of new internationally harmonisedguidances for the testing of pharmaceuticals for genotoxi-city [ICH guidances 52A and 52B, Muller et al., 1999].Within the OECD and ICH expert working groups workingon these documents, it was acknowledged that irrelevantresults may be produced under conditions of high toxicityand that this problem is most often encountered with the invitro chromosome aberration test and in the MLA [Muller etal., 1999]. However, during the ICH Expert Working Groupdeliberations: (1) exact concentration response informationon cytotoxicity and clastogenicity on a large variety ofcompounds were not available; (2) lack of data did notallow for a sufficient comparison of various measures ofcytotoxicity such as mitotic index, cell proliferation kinet-ics, inhibition of DNA synthesis, cloning efficiency, cultureconfluency; and (3) ideal means of cytotoxicity determina-tion for the various cell types in use could not be delineated.Regarding the MLA, the data that were reviewed under ICHauspicies indicated that below a level of 20% survival manynoncarcinogenic and Salmonella negative compounds havebeen found to produce elevated mutation frequencies [Gar-riott et al., 1995]. However, lack of reliable data led to theconclusion that caution is due with positive results ob-tained at levels of survival lower than 10% in the ICH S2Aguidance.
Within the IWGTP, several options to address and pos-sibly solve the problem of appropriate levels of cytotoxicityhave been presented and discussed.
TABLE I. Summary of Genotoxicity Results for StandardBattery Tests Submitted for Registration of 335 NewPharmaceutical Entities to the German Federal Institute forDrugs and Medical Devices Between 1990 and 1997
No. ofcompounds with
Percent ofcompounds with
Bacterial reversemutation 298 23 7.7%
Mouse lymphoma tkassay 104 28 26.9%
HPRT test 162 6 3.7%Chromosome
aberrations in vitro 266 77 28.9%In vivo bone marrow 283 19 6.7%
TABLE II. Criteria Identified in the ICH S2A Guidance onSpecific Aspects of Regulatory Genotoxicity Tests forPharmaceuticals to Judge the Relevance of an In Vitro TestResult
For in vitro positive results Attributable to a contaminant? Due to in vitro specific metabolic pathway or metabolite? Response not concentration related? For weak/equivocal responses, is effect reproducible? Is effect due to extreme culture conditions (pH, osmolality, heavyprecipitate especially in cell suspensions) that will not oc